end-stage knee joint disease
Conditions
Interventions
the IV and IA TXA group:20mg/kg of TXA administered intravenously 30 minutes before incising skin and 3.0g TXA (total 60ml solution) administered into the knee capsule before sutured.
IV NS and IA TXA group:the same IV dosage of 0.9% normal saline(NS) administered intravenously 30 minutes before incising skin and 3.0g TXA(total 60ml solution) administered into knee capsule before s
Sponsors
Orthopeadic Department, West China hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
83 Years to 49 Years
Inclusion criteria
Inclusion criteria: 1. RTKA for prosthetic joint infection(PJI); 2. both first-stage and second-stage revision performed in our department; 3. at least a 3-week follow-up after the second-stage revision; 4. normal clotting mechanism and effectively controlled medical diseases(diabetes mellitus and hypertension, etc.).
Exclusion criteria
Exclusion criteria: 1. primary total knee arthroplasty; 2. revision total knee arthroplasty for fracture or other non-infection factors; 3. patients currently receiving anticoagulant therapy; 4. severe hepatic, renal, cardiovascular or respiratory diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| preoperative Hb;postoperative 48-hr Hb;postoperative 48-hr drainage;venous thromboembolism including DVT and PE; | — |
Countries
China
Contacts
Public ContactXianlong Zhang
The Sixth People's Hospital of Shanghai
Outcome results
None listed